HC Wainwright reiterated their buy rating on shares of uniQure (NASDAQ:QURE – Free Report) in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a $25.00 price objective on the biotechnology company’s stock.
Separately, Mizuho dropped their price objective on uniQure from $7.00 to $6.00 and set a neutral rating on the stock in a report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $23.00.
Check Out Our Latest Research Report on QURE
uniQure Stock Down 12.0 %
uniQure (NASDAQ:QURE – Get Free Report) last posted its earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.31) by ($0.05). The company had revenue of $8.49 million for the quarter, compared to analyst estimates of $2.58 million. uniQure had a negative return on equity of 121.60% and a negative net margin of 1,562.22%. Sell-side analysts predict that uniQure will post -4.45 EPS for the current fiscal year.
Hedge Funds Weigh In On uniQure
Hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its position in shares of uniQure by 222.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,258 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 4,315 shares in the last quarter. Vanguard Personalized Indexing Management LLC purchased a new position in uniQure during the fourth quarter worth approximately $86,000. SG Americas Securities LLC purchased a new position in uniQure during the fourth quarter worth approximately $116,000. Virtu Financial LLC purchased a new stake in uniQure in the fourth quarter valued at $195,000. Finally, Harbor Capital Advisors Inc. raised its position in uniQure by 21.1% in the fourth quarter. Harbor Capital Advisors Inc. now owns 30,883 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 5,389 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.
uniQure Company Profile
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
See Also
- Five stocks we like better than uniQure
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Sales Breakout Sends This Semiconductor Stock to Record High
- What does consumer price index measure?
- Surprise Buying Opportunity on This Dividend Aristocrat
- The Significance of Brokerage Rankings in Stock Selection
- New Theme Park Powerhouse: Merger Creates Industry-Leading Stock
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.